Important regulatory notice. Retatrutide is investigational and not licensed in the United Kingdom for human or veterinary use. Tirzepatide (Mounjaro) is licensed in the United Kingdom for type 2 diabetes and weight management on the prescription of a registered prescriber. This page is a research-context comparison of receptor pharmacology, trial design and UK regulatory status. It is not medical advice, not a therapeutic recommendation, and not an endorsement of any human use of either compound. Peptides Lab UK supplies research-use-only laboratory reference compounds with batch-specific HPLC certificates of analysis. Products are not for human or veterinary use.
Quick research summary. Tirzepatide is a dual GLP-1 and GIP receptor agonist licensed in the United Kingdom. Retatrutide is an investigational triple GLP-1, GIP and glucagon-receptor agonist currently in Phase 3 clinical development. The two compounds differ in receptor profile, trial-development stage and UK regulatory status. They are not directly comparable as consumer products because retatrutide is not a consumer product in the United Kingdom.
Receptor pharmacology comparison
| Feature | Tirzepatide | Retatrutide |
|---|---|---|
| GLP-1 receptor activity | Yes | Yes |
| GIP receptor activity | Yes | Yes |
| Glucagon receptor activity | No | Yes |
| Receptor classification | Dual incretin agonist | Triple incretin agonist |
This table summarises the receptor-binding profile reported in the published pharmacology literature. The presence of glucagon-receptor activity is the principal mechanistic distinction between the two molecules.
Clinical trial development stage
Tirzepatide completed the SURPASS programme (in type 2 diabetes) and the SURMOUNT programme (in weight management) and received UK marketing authorisation. It is available on prescription in the UK as Mounjaro. Retatrutide is currently in the Phase 3 TRIUMPH programme, scheduled to read out across 2026, and has not received any marketing authorisation in any jurisdiction at the time of writing.
UK regulatory status
| Compound | UK status | Legal route to access |
|---|---|---|
| Tirzepatide (Mounjaro) | MHRA-licensed | Prescription from a registered prescriber |
| Retatrutide | Investigational, unlicensed | MHRA-authorised clinical trial only (NIHR Be Part of Research portal) |
Anyone considering either compound for clinical use in the United Kingdom should speak to a registered prescriber. The Guardian (4 April 2026) reported that the MHRA is investigating UK clinics making therapeutic claims about unregulated peptide products. Retatrutide marketed online in the United Kingdom for human use sits outside that regulatory framework.
Trial-design differences
The two clinical programmes are not directly comparable. They tested different patient populations, used different titration schedules, ran for different durations, and used different primary endpoints. Cross-trial comparison without statistical adjustment is a known source of error in pharmacology reviews. Independent meta-analyses are the appropriate place to look for any quantitative comparison once both programmes have completed.
What the public Phase II retatrutide protocol used
The Phase II retatrutide trial (Jastreboff et al, NEJM, June 2023) used a 4-week step titration starting at 1 mg per week, escalating to 4 mg, 8 mg and 12 mg. This is a description of the trial design only. It is not transferable to personal use and cannot legally be replicated outside an authorised clinical-trial setting in the United Kingdom.
For laboratory researchers
Both retatrutide and tirzepatide are available as research-use-only laboratory reference compounds for in-vitro work and analytical chemistry. Quality requirements are the same in both cases: batch-specific certificate of analysis, third-party HPLC purity data, mass-spectrometry identity confirmation, and clear research-use-only labelling. Peptides Lab UK supplies both on that basis. We do not provide dosing or therapeutic guidance and our products are not for human or veterinary use.
For UK consumers reading about either compound
Tirzepatide is licensed in the United Kingdom and available on prescription through your GP, NHS weight-management pathways or licensed online pharmacies. Retatrutide is not licensed in the United Kingdom and is not legally available for personal use outside an authorised clinical trial. Strong personal-outcome claims about either compound from non-pharmacy sources should be treated with caution.
Frequently Asked Questions
Is retatrutide approved for human use in the UK?
No. Retatrutide has not received MHRA, EMA or FDA marketing authorisation. It is in Phase 3 clinical development.
Is tirzepatide approved for human use in the UK?
Yes. Tirzepatide is licensed in the United Kingdom (Mounjaro) and is available on prescription for type 2 diabetes and for weight management within defined clinical pathways.
Can the two compounds be compared as personal-use options?
No. Only one of the two has UK marketing authorisation. The other is investigational and not legally available outside an authorised clinical trial.
What is the receptor difference?
Tirzepatide is a dual GLP-1 and GIP receptor agonist. Retatrutide is a triple GLP-1, GIP and glucagon receptor agonist. The glucagon-receptor component is the principal mechanistic distinction.
Where can I read the source clinical literature?
NEJM has published Phase II data for retatrutide (Jastreboff et al, June 2023, doi 10.1056/NEJMoa2301972) and the SURPASS and SURMOUNT programmes for tirzepatide. These are indexed on PubMed.
Research use only. This page is a literature-context comparison of receptor pharmacology and UK regulatory status. It is not medical, clinical or therapeutic advice. Retatrutide is investigational and not licensed in the United Kingdom. Tirzepatide is prescription-only. Peptides Lab UK supplies research-use-only laboratory reference compounds with batch-specific certificates of analysis. Products are not for human or veterinary use.
